Drug Profile
Birch pollen extract - Stallergenes Greer plc
Alternative Names: Bet v 1; Bet v 1a; Oralair Bet V 1 recombinant allergen; Oralair Birch; rBet v 1; Staller (Birch); Staloral Birch; STALORAL® Birch 300 IRLatest Information Update: 01 Jun 2023
Price :
$50
*
At a glance
- Originator Stallergenes SA
- Developer Endo International; Stallergenes Greer plc; Stallergenes SA
- Class Allergens; Peptide vaccines; Peptides; Skin disorder therapies; Tree pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Seasonal allergic rhinitis
Most Recent Events
- 25 May 2023 Phase-III clinical trials in Seasonal allergic rhinitis in European Union (Sublingual) (In children, In adolescents) (NCT05668390)
- 03 Jan 2023 Stallergenes Greer plans a phase III trial for Allergic rhinoconjunctivitis (In Children, In adolescents) in October 2023 (NCT05668390)
- 14 Sep 2022 Stallergenes initiates phase III trial for Seasonal allergic rhinitis (In children, In adolescents) in Austria, France and Sweden (Sublingual) (EudraCT2022-002012-23)